Her2-targeted therapies are safe and effective drugs for Her2-positive breast cancer; however, de novo or acquired resistance to these agents has limited their clinical efficacy, which ultimately leads to disease relapse and tumor progression. Here, ERBB2 is linked to neoplasm.